SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors ofA Iovance Biotherapeutics, Inc.A ("Iovance" or the "Company")A (NASDAQ:A IOVA).A  Such investors are advised to contact Robert S. Willoughby atA or 888-476-6529, ext. 7980.The investigation concerns whether Iovance and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.A  [Click here for information about joining the class action]A On October 5, 2020, post-market, Iovance issued a press release "provid[ing] a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifileucel in metastatic melanoma."A  Specifically, Iovance advised investors that "the Company and the [U.S. Food and Drug Administration] have not been able to agree on the required potency assays to fully define its TIL therapy, which is required as part of a BLA [Biologics License Application] submission. A The Company is continuing to refine the information from its current potency assays and simultaneously developing additional assays. A As a result of these developments, the BLA submission is not expected by the end of 2020."A  On this news, Iovance's stock price fell $3.96 per share, or 12.35%, to close at $28.10 per share on October 6, 2020.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2022    »